Hydroxypropyl betadex - Vtesse/NIH

Drug Profile

Hydroxypropyl betadex - Vtesse/NIH

Alternative Names: 2-Hydroxypropyl-B-Cyclodextrin; 2-Hydroxypropyl-beta-cyclodextrin; HP-beta-CD; HPBCD; IT-HPBCD; Kleptose; VTS 270

Latest Information Update: 17 Mar 2017

Price : $50

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Vtesse
  • Class Beta-Cyclodextrins
  • Mechanism of Action Binding agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Niemann-Pick disease type C
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Niemann-Pick disease type C

Most Recent Events

  • 15 Mar 2017 Vtesse completes enrolment in its phase II/III trial for Niemann-Pick disease type C (In adolescents, In adults, In children) in USA, Germany, United Kingdom, France, Spain, Australia, Turkey
  • 29 Nov 2016 Hydroxypropyl betadex receives Rare Pediatric Disease designation for Niemann-Pick Type C1 disease in USA
  • 02 Nov 2016 Hydroxypropyl betadex receives Promising Innovative Medicine designation for Niemann-Pick Type C1 disease in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top